Earnings Preview: CytomX to Report Financial Results Pre-market on May 12
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Catapults 76% Though Its Price And Business Still Lag The Industry
$CTMX Stock Is up 8% Today. Here's What We See in Our Data.
These Are the Sectors Best Liked Within Defensive and Cyclicals Groups – Morgan Stanley
Press Release: CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $2.5
12 Health Care Stocks Moving In Monday's After-Market Session
Express News | CytomX Therapeutics Presents Preclinical Data for Mrna Encoded Masked Il-12 Molecule in Collaboration With Moderna at AACR Annual Meeting
CytomX Therapeutics Presents Preclinical Data for MRNA Encoded Masked IL-12 Molecule in Collaboration With Moderna at AACR Annual Meeting
Piper Sandler Initiates CytomX(CTMX.US) With Hold Rating, Announces Target Price $2.5
Piper Sandler Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $2.5
CytomX Therapeutics Participates in a Conference Call With JPMorgan
Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled!
Insider Sale: CEO of $CTMX Sells 37,656 Shares
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability
CytomX Therapeutics' Earnings Call Highlights Progress and Challenges
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now